Mesabi(MSB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MSB Mesabi

Market Closed 07-10 16:00:00 EDT

25.10

-0.23

-0.91%

盘后25.10

+0.000.00%

16:10 EDT

High25.90	Low24.74	Vol38.99K
Open25.31	D1 Closing25.33	Amplitude4.58%
Mkt Cap329.31M	Tradable Cap329.06M	Total Shares13.12M
T/O977.98K	T/O Rate0.30%	Tradable Shares13.11M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MSB","market":"US","secType":"STK","nameCN":"Mesabi","latestPrice":25.1,"timestamp":1783713600000,"preClose":25.33,"halted":0,"volume":38988,"hourTrading":{"tag":"盘后","latestPrice":25.1,"preClose":25.1,"latestTime":"16:10 EDT","volume":31,"amount":778.1,"timestamp":1783714204456,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.009080142123963556,"floatShares":13109915,"shares":13120010,"eps":0.863187,"marketStatus":"Market Closed","change":-0.23,"latestTime":"07-10 16:00:00 EDT","open":25.31,"high":25.9,"low":24.74,"amount":977982,"amplitude":0.045795,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.863187,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1783929600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":25.33,"dividendRate":0.038247,"preHourTrading":{"tag":"盘前","latestPrice":24.66,"preClose":25.33,"latestTime":"09:20 EDT","volume":200,"amount":4932,"timestamp":1783689647314,"change":-0.67,"changeRate":-0.026451,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":25.1,"preClose":25.1,"latestTime":"16:10 EDT","volume":31,"amount":778.1,"timestamp":1783714204456,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.1696236259710104,"impliedVol":0.5632,"impliedVolPercentile":0.6375},"requestUrl":"/m/hq/s/MSB/wiki","defaultTab":"wiki","newsList":[{"id":"2650157507","title":"Mesoblast (ASX:MSB) Is Up 8.7% After Strong Ryoncil Debut And FDA BLA Milestone - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2650157507","media":"Simply Wall St.","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650157507?lang=en_us&edition=fundamental","pubTime":"2026-07-12 08:28","pubTimestamp":1783816116,"startTime":"0","endTime":"0","summary":"In July 2026, Mesoblast reported that the FDA had accepted its Biologics License Application for rexlemestrocel‑L in preventing life‑threatening gastrointestinal bleeding in end‑stage heart failure patients with LVADs, while the therapy continued to benefit from Orphan Drug and RMAT designations under newly clarified, more flexible FDA guidance for rare diseases.\nSeparately, Mesoblast disclosed record Ryoncil net revenue of US$36,000,000 for the quarter and US$115,000,000 for its first full...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-87-after-strong-ryoncil-debut-and-fda","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-87-after-strong-ryoncil-debut-and-fda","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","LABU","BK7067","MSB.AU","BK4588","BK4585","BK4006","BK7508","MSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650390813","title":"Press Release: Ryoncil(r) Delivers Net Revenue of Us$36m for the Fourth Quarter Ended 30 June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2650390813","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650390813?lang=en_us&edition=fundamental","pubTime":"2026-07-10 08:30","pubTimestamp":1783643400,"startTime":"0","endTime":"0","summary":"NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil(R) (remestemcel-","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK4575","BK4150","BK4022","BK7508","MSB.AU","BK4139","MESO","MSB","BK4232","BK7501","MSC","R","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648015660","title":"Why Mesoblast (ASX:MSB) Is Up 9.3% After FDA Accepts Modular BLA Review For Rexlemestrocel-L","url":"https://stock-news.laohu8.com/highlight/detail?id=2648015660","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648015660?lang=en_us&edition=fundamental","pubTime":"2026-07-04 00:35","pubTimestamp":1783096506,"startTime":"0","endTime":"0","summary":"In late June 2026, Mesoblast received a Biologics License Application filing number from the U.S. FDA and requested modular review for rexlemestrocel-L to prevent life-threatening gastrointestinal bleeding in end-stage heart failure patients supported by left ventricular assist devices, building on its Orphan Drug and RMAT designations.\nThe filing comes as new FDA draft guidance reiterates a flexible approach to therapies for rare, high-mortality conditions, potentially aligning closely with...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/why-mesoblast-asxmsb-is-up-93-after-fda-accepts-modular-bla","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/why-mesoblast-asxmsb-is-up-93-after-fda-accepts-modular-bla","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","BK7067","BK7508","BK4006","LABU","MSB.AU","MSB","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648500937","title":"Treasure Global Recieves Canadian MSB Registration for OXI Wallet Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2648500937","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648500937?lang=en_us&edition=fundamental","pubTime":"2026-07-02 20:51","pubTimestamp":1782996702,"startTime":"0","endTime":"0","summary":"Treasure Global  said Thursday it received access to a Canadian Money Services Business registration, supporting the expansion of its OXI Wallet platform.The company said it plans to add cross-border payments, remittances, foreign exchange, stablecoin settlements, and fiat-to-crypto and crypto-to-fiat conversion services.Treasure Global said it also plans to expand OXI Wallet across the Asia-Pacific region by integrating with regional payment networks, including DuitNow and PayNow.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TGL","BK4009","MSB","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648957086","title":"Is Mesoblast (ASX:MSB) Undervalued Following FDA Progress For Rexlemestrocel L?","url":"https://stock-news.laohu8.com/highlight/detail?id=2648957086","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648957086?lang=en_us&edition=fundamental","pubTime":"2026-07-02 13:40","pubTimestamp":1782970812,"startTime":"0","endTime":"0","summary":"Why this FDA milestone matters for Mesoblast\nMesoblast (ASX:MSB) stock is in focus after the US FDA assigned a Biologics License Application filing number for rexlemestrocel-L and accepted a modular review request for patients with LVAD-related risks.\nThis regulatory step, supported by existing Orphan Drug and Regenerative Medicine Advanced Therapy designations, provides formal structure around the approval process for Mesoblast’s late-stage heart failure program and clarifies the path for...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-undervalued-following-fda-progress-for-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-undervalued-following-fda-progress-for-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","LU2065732104.USD","PRGS","BK4006","BK4585","LABU","MSB","BK4097","BK7067","BK7508","MSB.AU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648359593","title":"Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs","url":"https://stock-news.laohu8.com/highlight/detail?id=2648359593","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648359593?lang=en_us&edition=fundamental","pubTime":"2026-07-01 08:38","pubTimestamp":1782866280,"startTime":"0","endTime":"0","summary":"NEW YORK, June  30, 2026  (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/01/3320270/0/en/Mesoblast-Receives-BLA-Filing-Number-and-Requests-Modular-Review-for-Rexlemestrocel-L-in-Patients-with-End-Stage-Heart-Failure-and-LVADs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4150","MESO","LU0368265418.SGD","LU0170899867.USD","LU0266512473.USD","LU0788109394.HKD","IE00BSNM7G36.USD","LU0300736492.USD","BK4138","BK4139","MSB","LU0266512127.USD","LU0300736062.USD","BK4575","MSC","BK4006","LU0122376428.USD","LU0456854461.SGD","BK4588","BK4585","LABU","MPC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647735143","title":"OwlTing Group (NASDAQ: OWLS) and Saber Money Open Settlement into India's US$860 Billion Export Economy","url":"https://stock-news.laohu8.com/highlight/detail?id=2647735143","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647735143?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:21","pubTimestamp":1782728460,"startTime":"0","endTime":"0","summary":"Integration with Saber Money brings India rupee payout and Eurozone and UK payment access to OwlPay Harbor, opening a near real-time settlement path into one of the world’s largest cross-border paymen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/29/3318784/0/en/OwlTing-Group-NASDAQ-OWLS-and-Saber-Money-Open-Settlement-into-India-s-US-860-Billion-Export-Economy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OWLS","IYW","QDTE","QQQE","TQQQ","QQQY","MNQmain","MSB","QYLG","GPIQ","NDX","BK4227","ONEQ","QID","QQQ","JEPQ","QLD","QQQM","NQmain","TECS","TQQY","BK4006","NVIW.SI","FTEC","PSQ","SQQQ",".IXIC","QQQA","QQQJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646847290","title":"Press Release: Mesoblast Draws US$50 Million from Five-year Non-dilutive Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2646847290","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646847290?lang=en_us&edition=fundamental","pubTime":"2026-06-25 08:59","pubTimestamp":1782349140,"startTime":"0","endTime":"0","summary":"Optimized capital structure, retiring short-term maturing debtWell-funded for commercial operations and growth pipelineNEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:M","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK4232","R","MSB.AU","MSB","BK4150","BK4006","MSC","BK4575","BK7501","BK7067","MESO","BK4139","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645965180","title":"Mesoblast (ASX:MSB) Is Up 9.2% After Ryoncil’s Near-US$100m Debut And Revascor FDA Progress – Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2645965180","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645965180?lang=en_us&edition=fundamental","pubTime":"2026-06-21 00:29","pubTimestamp":1781972983,"startTime":"0","endTime":"0","summary":"Earlier this week, Mesoblast reported that Ryoncil’s first-year US launch revenue approached about US$100 million, alongside continued FDA engagement on an accelerated-approval pathway and Biologics License Application for heart failure therapy Revascor.\nThis combination of early commercial traction for Ryoncil and active regulatory dialogue on Revascor has sharpened investor focus on Mesoblast’s broader cell therapy pipeline and execution risks.\nWe’ll now examine how Ryoncil’s early US...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-92-after-ryoncils-near-us100m-debut-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-92-after-ryoncils-near-us100m-debut-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LABU","PRGS","BK4006","BK7508","BK4585","BK7501","MSB","BK7067","BK4588","BK4097","MSB.AU","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643218325","title":"Mesabi Trust Q1 FY27 net income drops 70.05% to $1.09 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2643218325","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643218325?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:17","pubTimestamp":1781295446,"startTime":"0","endTime":"0","summary":"Mesabi Trust net income fell to USD 1.09 million, down from USD 3.63 million a year earlier; net income per unit slid to USD 0.08 from USD 0.28.Total revenues dropped to USD 2.25 million from USD 4.73 million, as royalty income sank to USD 2.08 million from USD 4.35 million.Bonus royalties were absent versus USD 1.78 million a year earlier; base overriding royalties eased to USD 1.89 million from USD 2.43 million.Distributions declared per unit declined to USD 0.24 from USD 0.56; expenses edged up to USD 1.16 million from USD 1.1 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesabi Trust published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system ope","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL1SZR2S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","MSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640998815","title":"Press Release: Mesabi Metallics Monetizes Portion of Royalty Interest for $265 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2640998815","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640998815?lang=en_us&edition=fundamental","pubTime":"2026-06-02 07:32","pubTimestamp":1780356720,"startTime":"0","endTime":"0","summary":"The $2.5 billion world-scale, low-cost DR-grade iron ore mine positions U.S. steel industry to break free from foreign imports from Brazil and other countries. The transaction further validates the exceptional quality, scale and long-term strategic importance of Mesabi Metallics' world-class Direct Reduction  grade iron ore mine, beneficiation plant and pellet plant in Minnesota, which is expected to commence production in the third quarter of 2026.\"TMCR's investment is a powerful third-party validation of the quality and strategic importance of Mesabi,\" said Artem Matyushok, Board Member of Mesabi Metallics. \"As the United States works to rebuild domestic industrial capacity and secure critical supply","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4168","TMCR","MSB","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640671409","title":"The Metals Royalty Company Inc. Closes Mesabi Royalty Acquisition, Exercises Option to Acquire an Additional 1% Royalty Interest and Appoints Michael Hess as Non-Executive Co-Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2640671409","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640671409?lang=en_us&edition=fundamental","pubTime":"2026-06-02 05:30","pubTimestamp":1780349408,"startTime":"0","endTime":"0","summary":"London, UK, June 1st, 2026, FinanceWire 1% Royalty Acquisition on One of the United States’ Only Large-Scale Sources of Merchant DR-Grade Iro...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/the-metals-royalty-company-inc-closes-mesabi-royalty-acquisition-exercises-option-to-acquire-an-additional-1-royalty-interest-and-appoints-michael-hess-as-non-executive-co-chairman?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/the-metals-royalty-company-inc-closes-mesabi-royalty-acquisition-exercises-option-to-acquire-an-additional-1-royalty-interest-and-appoints-michael-hess-as-non-executive-co-chairman?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4213","BK4006","LU0266512127.USD","LU0788109394.HKD","LU0300736062.USD","LU0300736492.USD","BK4535","MSB","LU0368265418.SGD","LU0122376428.USD","BK4588","IE00B19Z3B42.SGD","LU0456854461.SGD","PICK","IE00B19Z3581.USD","IE0002270589.USD","BK4585","IE00B7SZLL34.SGD","HES","LU1169589451.USD","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640626979","title":"The Metals Royalty Company Acquires Mesabi Royalty; Names Michael Hess as Non-Executive Co-Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2640626979","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640626979?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:42","pubTimestamp":1780346579,"startTime":"0","endTime":"0","summary":"The Metals Royalty Company  said late Monday it closed the acquisition of a 1.0% index-priced gross overriding production royalty with a revenue floor in the Mesabi Metallics iron ore project located in Nashwauk, Minnesota.The acquisition of the initial royalty was funded concurrently with proceeds from an upsized $80.1 million private placement at $13.00 per share, and a net $43 million draw under its senior secured acquisition credit facility entered into on June 1, the company said.An additional $7 million delayed draw will be accessible when it completes the acquisition of the additional 1.0% royalty, the company added.The company said it has exercised the option to buy an additional 1.0% royalty on the same terms as the initial royalty, provided the closing conditions including raising the necessary funding, are satisfied before July 31.Mesabi Metallics is targeting commissioning of operations in the second half of 2026, the company said.Metals Royalty added that it has appointed ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0122376428.USD","BK4535","LU0456854461.SGD","PICK","BK4585","LU0266512127.USD","LU0300736062.USD","BK4213","IE00B7SZLL34.SGD","TMCR","BK4006","IE00B19Z3581.USD","LU0788109394.HKD","MSB","LU1169589451.USD","LU0368265418.SGD","LU0300736492.USD","LU1169590202.USD","BK4168","IE00B19Z3B42.SGD","IE0002270589.USD","HES","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633972051","title":"Assessing Mesoblast (ASX:MSB) Valuation After Phase 3 Recruitment Milestone For Rexlemestrocel L","url":"https://stock-news.laohu8.com/highlight/detail?id=2633972051","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633972051?lang=en_us&edition=fundamental","pubTime":"2026-05-07 11:57","pubTimestamp":1778126267,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) has reached full patient recruitment for its pivotal Phase 3 trial of rexlemestrocel-L in chronic low back pain, a key step toward confirmatory data supporting a potential US regulatory filing.\nSee our latest analysis for Mesoblast.\nDespite the latest clinical milestone, Mesoblast’s 1 day share price return of a 4.13% decline and 7 day share price return of a 5.86% decline show some cooling momentum. However, the 3 year total shareholder return of 102.23% reflects a strong...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblast-asxmsb-valuation-after-phase-3-recruitme","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblast-asxmsb-valuation-after-phase-3-recruitme","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4006","MSB.AU","BK7067","BK7508","BK7501","MSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633625909","title":"Mesabi Trust Reports Higher Shipments But No Bonus Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2633625909","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633625909?lang=en_us&edition=fundamental","pubTime":"2026-05-05 06:37","pubTimestamp":1777934254,"startTime":"0","endTime":"0","summary":"Mesabi Shs ( ($MSB) ) just unveiled an update. Mesabi Trust reported that, according to a quarterly royalty report from Cleveland-Cliffs, it receiv...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesabi-trust-reports-higher-shipments-but-no-bonus-royalties?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesabi-trust-reports-higher-shipments-but-no-bonus-royalties?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4006","MSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632227266","title":"Is Completing Phase 3 Enrollment For Rexlemestrocel-L Reshaping The Investment Case For Mesoblast (ASX:MSB)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2632227266","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632227266?lang=en_us&edition=fundamental","pubTime":"2026-05-02 11:34","pubTimestamp":1777692888,"startTime":"0","endTime":"0","summary":"In late April 2026, Mesoblast Limited reported it had completed patient recruitment for its pivotal 300-patient Phase 3 trial of rexlemestrocel-L in chronic low back pain due to degenerative disc disease, a placebo-controlled study designed around a 12-month pain reduction endpoint and supported by the therapy’s RMAT designation.\nThis milestone moves rexlemestrocel-L closer to potential FDA submission for a condition affecting over 7 million Americans and heavily tied to opioid use,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-completing-phase-3-enrollment-for-rexlemestrocel-l-reshap","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-completing-phase-3-enrollment-for-rexlemestrocel-l-reshap","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB","BK7067","BK7508","BK7501","MSB.AU","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631555111","title":"Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2631555111","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631555111?lang=en_us&edition=fundamental","pubTime":"2026-04-29 08:53","pubTimestamp":1777423980,"startTime":"0","endTime":"0","summary":"NEW YORK, April  28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/29/3283366/0/en/Mesoblast-Achieves-Patient-Recruitment-Target-in-Pivotal-Phase-3-Trial-for-Chronic-Low-Back-Pain.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB","BK4588","BK4551","MESO","BK4585","DDD","BK4150","BK4161","BK4546","BK4139","MSC","BK4575","BK4006","BK4170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629750895","title":"Mesabi Trust (MSB) Q3 Net Margin Strengthens Bearish Dividend Coverage Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2629750895","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629750895?lang=en_us&edition=fundamental","pubTime":"2026-04-24 10:19","pubTimestamp":1776997156,"startTime":"0","endTime":"0","summary":"Mesabi Trust (MSB) has put fresh FY 2026 numbers on the table, with third quarter revenue of US$3.6 million, basic EPS of US$0.21 and net income of US$2.8 million. The trust has seen quarterly revenue move between US$4.7 million and US$6.9 million and EPS range from US$0.28 to US$0.46 over the past year of reported periods, alongside net income between US$3.6 million and US$6.1 million. This sets a clear context for the latest print. With a trailing net margin of 82.8% and earnings quality...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/2055000-choice2-main-header/1585186660639","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2055000-choice2-main-header/1585186660639"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-msb/mesabi-trust/news/mesabi-trust-msb-q3-net-margin-strengthens-bearish-dividend","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-msb/mesabi-trust/news/mesabi-trust-msb-q3-net-margin-strengthens-bearish-dividend","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB","BK7067","BK7508","BK7501","MSB.AU","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629078725","title":"Mesabi Trust publishes fiscal 2026 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2629078725","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629078725?lang=en_us&edition=fundamental","pubTime":"2026-04-23 04:41","pubTimestamp":1776890470,"startTime":"0","endTime":"0","summary":"Mesabi Trust filed its annual report for fiscal year ended Jan. 31, 2026, highlighting weaker royalty-driven performance tied to lower pellet shipments and pricing at Northshore.Pellet production and shipments from Mesabi Trust lands fell to 3,493,854 tons from 3,862,061 tons.Trust reported reduced bonus royalty generation late in year as limited third-party pellet sales were priced below 2026 adjusted threshold price of USD 71.7 per ton.Mesabi Trust maintained a cash reserve to manage volatile royalties, with unallocated reserve declining to USD 20.4 million from USD 23.3 million.Arbitration against Northshore and Cleveland-Cliffs remained active, targeting damages tied to 2022–2023 idling and alleged underpayment on intercompany shipments since 2023.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shou","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL47BGhb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLF","BK4585","BK4588","MSB","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628762489","title":"Mesoblast (ASX:MSB) Is Up 6.1% After FDA Clears Registrational DMD Trial for Ryoncil","url":"https://stock-news.laohu8.com/highlight/detail?id=2628762489","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628762489?lang=en_us&edition=fundamental","pubTime":"2026-04-19 21:04","pubTimestamp":1776603864,"startTime":"0","endTime":"0","summary":"On 8 April 2026, Mesoblast Limited announced that the FDA granted Investigational New Drug clearance to proceed directly to a registrational trial of Ryoncil (remestemcel‑L‑rknd) in 76 children with Duchenne muscular dystrophy, using time‑to‑stand at nine months as the primary endpoint.\nThis marks an expansion of Ryoncil’s use beyond steroid‑refractory acute graft‑versus‑host disease into another rare pediatric indication, leveraging its existing FDA‑approved manufacturing platform and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-61-after-fda-clears-registrational-dm","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-61-after-fda-clears-registrational-dm","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK4006","BK4588","BK7508","BK4585","MSB","BK7501","LABU","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mesabi-trust.com","stockEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":0.027},{"period":"3month","weight":-0.1947},{"period":"6month","weight":-0.3684},{"period":"1year","weight":0.015},{"period":"ytd","weight":-0.3484}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1111},{"period":"6month","weight":0.0877},{"period":"1year","weight":0.2063},{"period":"ytd","weight":0.1071}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mesabi Trust, a royalty trust, engages in iron ore mining business in the United States. Mesabi Trust was founded in 1961 and is based in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.565217,"avgChangeRate":0.059897},{"month":2,"riseRate":0.565217,"avgChangeRate":0.031389},{"month":3,"riseRate":0.413043,"avgChangeRate":0.011673},{"month":4,"riseRate":0.382979,"avgChangeRate":-0.006266},{"month":5,"riseRate":0.510638,"avgChangeRate":0.00885},{"month":6,"riseRate":0.361702,"avgChangeRate":-0.010047},{"month":7,"riseRate":0.340426,"avgChangeRate":-0.00916},{"month":8,"riseRate":0.413043,"avgChangeRate":0.000339},{"month":9,"riseRate":0.413043,"avgChangeRate":0.003772},{"month":10,"riseRate":0.391304,"avgChangeRate":-0.005844},{"month":11,"riseRate":0.478261,"avgChangeRate":-0.001259},{"month":12,"riseRate":0.434783,"avgChangeRate":0.025908}],"exchange":"NYSE","name":"Mesabi","nameEN":"Mesabi"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mesabi(MSB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mesabi(MSB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mesabi,MSB,Mesabi股票,Mesabi股票老虎,Mesabi股票老虎国际,Mesabi行情,Mesabi股票行情,Mesabi股价,Mesabi股市,Mesabi股票价格,Mesabi股票交易,Mesabi股票购买,Mesabi股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mesabi(MSB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mesabi(MSB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction